Myocardial salvaging effect of telmisartan in experimental model of myocardial infarction

European Journal of Pharmacology

Volumn 619, Issue 1-3, 2009, Pages 75-84

  Goyal, Sameer ^a   Arora, Sachin ^a   Mittal, Rajan ^b   Joshi, Sujata ^a   Nag, Tapas C ^a   Ray, Ruma ^a   Kumari, Santosh ^c   Arya, Dharamvir Singh ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

^c INDIAN AGRICULTURAL RESEARCH INSTITUTE   (India)

Author keywords

Angiotensin II receptor blocker; Myocardial infarction; Oxidative stress; PPAR (peroxisome proliferator activated receptor gamma); Telmisartan

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CATALASE; CREATINE KINASE MB; GLUTATHIONE; ISOPRENALINE; LACTATE DEHYDROGENASE; MALONALDEHYDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SUPEROXIDE DISMUTASE; TELMISARTAN;

ACUTE HEART INFARCTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOCHEMISTRY; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG DOSE COMPARISON; ENZYME ACTIVITY; EXPERIMENTAL MODEL; HEART CONTRACTION; HEART HEMODYNAMICS; HEART INFARCTION; HEART LEFT VENTRICLE DP-DT; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE PRESSURE; HEART PRELOAD; HEART PROTECTION; HISTOPATHOLOGY; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; RAT; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT OUTCOME; ULTRASTRUCTURE;

ANIMALS; BENZIMIDAZOLES; BENZOATES; BIOLOGICAL MARKERS; BODY WEIGHT; CARDIOTONIC AGENTS; CATALASE; DISEASE MODELS, ANIMAL; HEART; ISOPROTERENOL; L-LACTATE DEHYDROGENASE; LIPID PEROXIDATION; MALE; MYOCARDIAL INFARCTION; MYOCARDIUM; RATS; RATS, WISTAR; SUPEROXIDE DISMUTASE;

EID: 69749126953     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.07.026     Document Type: Article

References (68)

1. Aebi H. Catalase. In: Bergmeyer H.U. (Ed). Methods of Enzymatic Analysis (1974), Academic Press Inc. 673-685
2. Bakris G., Burgess E., Weir M., Davidai G., Koval S., and AMADEO Study Investigators. Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy. Kidney Int. 74 (2008) 364-369
3. Banerjee S.K., Sood S., Dinda A.K., Das T.K., and Maulik S.K. Chronic oral administration of raw garlic protects against isoproterenol-induced myocardial necrosis in rat. Comp. Biochem. Physiol. C 136 (2003) 377-386
4. Benson S.C., Pershadsingh H.A., Ho C.I., Chittiboyina A., Desai P., Pravenec M., Qi N., Wang J., Avery M.A., and Kurtz T.W. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 43 (2004) 993-1002
5. Benson S.C., Iguchi R., Ho C.I., Yamamoto K., and Kurtz T.W. Inhibition of cardiovascular cell proliferation by angiotensin receptor blockers: are all molecules the same?. J. Hypertens. 26 (2008) 973-980
6. Bibbins-Domingo K., Coxson P., Pletcher M.J., Lightwood J., and Goldman L. Adolescent overweight and future adult coronary heart disease. N. Engl. J. Med. 6 (2007) 2371-2379
7. Bohm M., Lee M., Kreutz R., Kim S., Schinke M., Djavidani B., Wagner J., Kaling M., Wienen W., Bader M., et al. Angiotensin II receptor blockade in TGR(mREN2)27: effects of renin-angiotensin-system gene expression and cardiovascular functions. J. Hypertens. 13 (1995) 891-899
8. Bohm M., Lippoldt A., Wienen W., Ganten D., and Bader M. Reduction of cardiac hypertrophy in TGR(mREN2)27 by angiotensin II receptor blockade. Mol. Cell. Biochem. 163 (1996) 217-221
9. Bradford M.M. A rapid and sensitive method for quantization of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72 (1976) 248-254
10. Cabaud P., and Wroblewski F. Colorimetric measurement of lactic dehydrogenase activity of body fluid. Am. J. Clin. Pathol. 30 (1958) 234-236
11. 2- production. Thromb. Haemost. 90 (2003) 317-325
12. De Bono D.P., and Boon N.A. Diseases of the cardiovascular system. In: Edwards C.R.W., and Boucheir I.A.S. (Eds). Davidson's Principles and Practice and Medicine (1992), Churchill Livingstone, Hong Kong 249-340
13. de Gasparo M., Catt K.J., Inagami T., Wright J.W., and Unger T. International union of pharmacology XXIII. The angiotensin II receptors. Pharmacol. Rev. 52 (2000) 415-472
14. Devika P.T., and Stanely Mainzen Prince P. Protective effect of (-)-epigallocatechin-gallate (EGCG) on lipid peroxide metabolism in isoproterenol induced myocardial infarction in male Wistar rats: a histopathological study. Biomed. Pharmacother. 62 (2008) 701-708
15. Geng D.F., Wu W., Jin D.M., Wang J.F., and Wu Y.M. Effect of peroxisome proliferator-activated receptor gamma ligand rosiglitazone on left ventricular remodeling in rats with myocardial infarction. Int. J. Cardiol. 113 (2006) 86-91
16. Goebel M., Clemenz M., and Unger T. Effective treatment of hypertension by AT(1) receptor antagonism: the past and future of telmisartan. Expert Rev. Cardiovasc. Ther. 4 (2006) 615-629
17. Goyal B.R., Mesariya P., Goyal R.K., and Mehta A.A. Effect of telmisartan on cardiovascular complications associated with streptozotocin diabetic rats. Mol. Cell. Biochem. 314 (2008) 123-131
18. Grassi G., Quarti-Trevano F., and Mancia G. Cardioprotective effects of telmisartan in uncomplicated and complicated hypertension. J. Renin Angiotensin Aldosterone Syst. 9 (2008) 66-74
19. Gupta S.K., Mohanty I., Talwar K.K., Dinda A., Joshi S., Bansal P., Saxena A., and Arya D.S. Cardioprotection from ischemia and reperfusion injury by Withania somnifera: a hemodynamic, biochemical and histopathological assessment. Mol. Cell. Biochem. 260 (2004) 39-47
20. Gutteridge J.M. The role of superoxide and hydroxyl radicals in phospholipid peroxidation catalysed by iron salts. FEBS Lett. 150 (1982) 454-458
21. Halliwell B., and Chirico S. Lipid peroxidation: its mechanism, measurement, and significance. Am. J. Clin. Nutr. 57 (1993) 715S-724S
22. Hamberg M., and Samuelsson B. Prostaglandin endoperoxides. Novel transformations of arachidonic acid in human platelets. Proc. Natl Acad. Sci. U.S.A. 71 (1974) 3400-3404
23. Hinoi T., Tomohiro Y., Kajiwara S., Matsuo S., Fujimoto Y., Yamamoto S., Shichijo T., and Ono T. Telmisartan, an angiotensin II type 1 receptor blocker, improves coronary microcirculation and insulin resistance among essential hypertensive patients without left ventricular hypertrophy. Hypertens. Res. 31 (2008) 615-622
24. Ikejima H., Imanishi T., Tsujioka H., Kuroi A., Kobayashi K., Shiomi M., Muragaki Y., Mochizuki S., Goto M., Yoshida K., and Akasaka T. Effects of telmisartan, a unique angiotensin receptor blocker with selective peroxisome proliferator-activated receptor-gamma-modulating activity, on nitric oxide bioavailability and atherosclerotic change. J. Hypertens. 26 (2008) 964-972
25. Imayama I., Ichiki T., Inanaga K., Ohtsubo H., Fukuyama K., Ono H., Hashiguchi Y., and Sunagawa K. Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor gamma. Cardiovasc. Res. 72 (2006) 184-190
26. Iqbal M., Dubey K., Anwer T., Ashish A., and Pillai K.K. Protective effects of telmisartan against acute doxorubicin-induced cardiotoxicity in rats. Pharmacol. Rep. 60 (2008) 382-390
27. Ito H., Nakano A., Kinoshita M., and Matsumori A. Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates myocardial ischemia/reperfusion injury in a rat model. Lab. Invest. 83 (2003) 1715-1721
28. Karthick M., and Stanely Mainzen Prince P. Preventive effect of rutin, a bioflavonoid, on lipid peroxides and antioxidants in isoproterenol-induced myocardial infarction in rats. J. Pharm. Pharmacol. 58 (2006) 701-707
29. Karthikeyan K., Bai B.R., and Devaraj S.N. Cardioprotective effect of grape seed proanthocyanidins on isoproterenol-induced myocardial injury in rats. Int. J. Cardiol. 115 (2007) 326-333
30. Kato M., Sada T., Mizuno M., Kitayama K., Inaba T., and Koike H. Effect of combined treatment with an angiotensin II receptor antagonist and an HMG-CoA reductase inhibitor on atherosclerosis in genetically hyperlipidemic rabbits. J. Cardiovasc. Pharmacol. 46 (2005) 556-562
31. Kjeldsen S.E., and Julius S. Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Am. Heart J. 148 (2004) 747-754
32. Kobayashi N., Ohno T., Yoshida K., Fukushima H., Mamada Y., Nomura M., Hirata H., Machida Y., Shinoda M., Suzuki N., and Matsuoka H. Cardioprotective mechanism of telmisartan via PPAR-gamma-eNOS pathway in dahl salt-sensitive hypertensive rats. Am. J. Hypertens. 21 (2008) 576-581
33. Loh H.K., Sahoo K.C., Kishore K., Ray R., Nag T.C., Kumari S., and Arya D.S. Effects of thalidomide on isoprenaline-induced acute myocardial injury: a haemodynamic, histopathological and ultrastructural study. Basic Clin. Pharmacol. Toxicol. 100 (2007) 233-239
34. Lopez A.D., and Murrau C.C. The global burden disease, 1990-2020. Nat. Med. 4 (1998) 1241-1243
35. Marklund S., and Marklund G. Involvement of the superoxide anion radical in the autoxidation of pyrogallol and a convenient assay for superoxide dismutase. Eur. J. Biochem. 47 (1974) 469-474
36. Mattioli A.V., Zennaro M., Bonatti S., Bonetti L., and Mattioli G. Regression of left ventricular hypertrophy and improvement of diastolic function in hypertensive patients treated with telmisartan. Int. J. Cardiol. 97 (2004) 383-388
37. Mohanty I., Arya D.S., Dinda A., Talwar K.K., Joshi S., and Gupta S.K. Mechanisms of cardioprotective effect of Withania somnifera in experimentally induced myocardial infarction. Basic Clin. Pharmacol. Toxicol. 94 (2004) 184-190
38. Moron M.S., Depierre J.W., and Mannervik B. Levels of glutathione, glutathione reductase and glutathione S-transferase activities in rat lung and liver. Biochem. Biophys. Acta 582 (1979) 67-78
39. Nakamura T., Nishi H., Kokusenya Y., Hirota K., and Miura Y. Mechanism of antioxidative activity of fluvastatin-determination of the active position. Chem. Pharm. Bull. 48 (2000) 235-237
40. Okhawa H., Oohishi N., and Yagi N. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Ann. Biochem. 95 (1979) 351-358
41. Padmanabhan M., and Prince P.S. Preventive effect of S-allylcysteine on lipid peroxides and antioxidants in normal and isoproterenol-induced cardiotoxicity in rats: a histopathological study. Toxicology 224 (2006) 128-137
42. Panda V.S., and Naik S.R. Cardioprotective activity of Ginkgo biloba Phytosomes in isoproterenol-induced myocardial necrosis in rats: a biochemical and histoarchitectural evaluation. Exp. Toxicol. Pathol. 60 (2008) 397-404
43. Rajadurai M., and Stanely Mainzen Prince P. Preventive effect of naringin on lipid peroxides and antioxidants in isoproterenol-induced cardiotoxicity in Wistar rats: biochemical and histopathological evidences. Toxicology 228 (2006) 259-268
44. Rajadurai M., and Stanely Mainzen Prince P. Preventive effect of naringin on cardiac markers, electrocardiographic patterns and lysosomal hydrolases in normal and isoproterenol-induced myocardial infarction in Wistar rats. Toxicology 230 (2007) 178-188
45. Rathore N., John S., Kale M., and Bhatnagar D. Lipid peroxidation and antioxidant enzymes in isoproterenol induced oxidative stress in rat tissues. Pharmacol. Res. 38 (1998) 297-303
46. Richer C., Fornes P., Cazaubon C., Domergue V., Nisato D., and Giudicelli J.F. Effects of long-term angiotensin II AT1 receptor blockade on survival, hemodynamics and cardiac remodeling in chronic heart failure in rats. Cardiovasc. Res. 41 (1999) 100-108
47. Sabeena Farvin K.H., Anandan R., Kumar S.H., Shiny K.S., Sankar T.V., and Thankappan T.K. Effect of squalene on tissue defense system in isoproterenol-induced myocardial infarction in rats. Pharmacol. Res. 50 (2004) 231-236
48. Sakai S., Miyauchi T., Irukayama-Tomobe Y., Ogata T., Goto K., and Yamaguchi I. Peroxisome proliferator-activated receptor-gamma activators inhibit endothelin-1-related cardiac hypertrophy in rats. Clin. Sci. 103 (2002) 16S-20S
49. Sawyer D.B., Siwik D.A., Xiao L., Pimentel D.R., Singh K., and Colucci W.S. Role of oxidative stress in myocardial hypertrophy and failure. J. Mol. Cell. Cardiol. 34 (2002) 379-388
50. Schafer A., Flierl U., Vogt C., Menninger S., Tas P., Ertl G., and Bauersachs J. Telmisartan improves vascular function and reduces platelet activation in rats with streptozotocin-induced diabetes mellitus. Pharmacol. Res. 56 (2007) 217-223
51. Schupp M., Janke J., Clasen R., Unger T., and Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 109 (2004) 2054-2057
52. Shiomi T., Tsutsui H., Hayashidani S., Suematsu N., Ikeuchi M., Wen J., Ishibashi M., Kubota T., Egashira K., and Takeshita A. Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 106 (2002) 3126-3132
53. Suchalatha S., and Shyamala Devi C.S. Protective effect of Terminalia chebula against experimental myocardial injury induced by isoproterenol. Indian J. Exp. Biol. 42 (2004) 174-178
54. Sugawara A., Takeuchi K., Uruno A., Ikeda Y., Arima S., Kudo M., Sato K., Taniyama Y., and Ito S. Transcriptional suppression of type 1 angiotensin II receptor gene expression by peroxisome proliferator-activated receptor-gamma in vascular smooth muscle cells. Endocrinology 142 (2001) 3125-3134
55. Takaya T., Kawashima S., Shinohara M., Yamashita T., Toh R., Sasaki N., Inoue N., Hirata K., and Yokoyama M. Angiotensin II type 1 receptor blocker telmisartan suppresses superoxide production and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice. Atherosclerosis 186 (2006) 402-410
56. Takeda K., Ichiki T., Tokunou T., Funakoshi Y., Iino N., Hirano K., Kanaide H., and Takeshita A. Peroxisome proliferator-activated receptor gamma activators downregulate angiotensin II type 1 receptor in vascular smooth muscle cells. Circulation 102 (2000) 1834-1839
57. Thompson J.A., and Hess M.L. The oxygen free radical system: a fundamental mechanism in the production of myocardial necrosis. Prog. Cardiovasc. Dis. 28 (1986) 449-462
58. Wagner J., Drab M., Bohlender J., Amann K., Wienen W., and Ganten D. Effects of AT1 receptor blockade on blood pressure and the renin-angiotensin system in spontaneously hypertensive rats of the stroke prone strain. Clin. Exp. Hypertens. 20 (1998) 205-221
59. Weidenbach R., Schulz R., Gres P., Behrends M., Post H., and Heusch G. Enhanced reduction of myocardial infarct size by combined ACE inhibition and AT(1)-receptor antagonism. Br. J. Pharmacol. 131 (2000) 138-144
60. White W.B., Lacourciere Y., and Davidai G. Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period. Am. J. Hypertens. 17 (2004) 347-353
61. Wienen W., Richard S., Champeroux P., and Audeval-Gerard C. Comparative antihypertensive and renoprotective effects of telmisartan and lisinopril after long-term treatment in hypertensive diabetic rats. J. Renin Angiotensin Aldosterone Syst. 2 (2001) 31-36
62. Yamagishi S., and Takeuchi M. Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property. Med. Hypotheses 2005 64 (2005) 476-478
63. Yamana A., Arita M., Furuta M., Shimajiri Y., and Sanke T. The angiotensin II receptor blocker telmisartan improves insulin resistance and has beneficial effects in hypertensive patients with type 2 diabetes and poor glycemic control. Diabetes Res. Clin. Pract. 82 (2008) 127-131
64. Yates J.C., Beamish R.E., and Dhalla N.S. Ventricular dysfunction and necrosis produced by adrenochrome metabolite of epinephrine: relation to pathogenesis of catecholamine cardiomyopathy. Am. Heart J. 102 (1981) 210-221
65. Yuan Z., Liu Y., Liu Y., Zhang J., Kishimoto C., Wang Y., Ma A., and Liu Z. Peroxisome proliferation-activated receptor-gamma ligands ameliorate experimental autoimmune myocarditis. Cardiovasc. Res. 59 (2003) 685-694
66. Yue T.L., Chen J., Bao W., Narayanan P.K., Bril A., Jiang W., Lysko P.G., Gu J.L., Boyce R., Zimmerman D.M., Hart T.K., Buckingham R.E., and Ohlstein E.H. In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. Circulation 104 (2001) 2588-2594
67. Zhou B., Wu L.J., Li L.H., Tashiro S., Onodera S., Uchiumi F., and Ikejima T. Silibinin protects against isoproterenol-induced rat cardiac myocyte injury through mitochondrial pathway after up-regulation of SIRT1. J. Pharmacol. Sci. 102 (2006) 387-395
68. Zhou R., Xu Q., Zheng P., Yan L., Zheng J., and Dai G. Cardioprotective effect of fluvastatin on isoproterenol-induced myocardial infarction in rat. Eur. J. Pharmacol. 586 (2008) 244-250